Atossa appoints Mark Daniel as CFO to lead finance for commercial readiness

ATOSSA THERAPEUTICS, INC.

Mark Daniel appointed CFO effective Oct 14; Heather Rees transitions to non-officer employee through Nov 15.
Daniel receives $415,900 base salary, 40% target bonus, and 578,000-share stock option grant vesting over 4 years.
Daniel brings 25+ years life-science finance; previously SVP Finance at Bruker Spatial Biology until 2025.
He has managed $400M cash portfolio and executed ~$1B in equity/debt transactions, supporting Atossa's commercial launch of (Z)-endoxifen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.